💊 GLP-1 Drugs
CagriSema — The Next Weight Loss Drug Showing 25% Results (2026)
CagriSema combines cagrilintide and semaglutide, showing 25% weight loss in trials. Complete guide to this next-generation obesity drug. Updated January 2026.
Key Takeaways
- CagriSema produced average 22.7% weight loss at 68 weeks in the REDEFINE 1 trial
- It combines cagrilintide (amylin analogue) + semaglutide in one weekly injection
- Amylin agonism adds appetite suppression through a completely different brain pathway
- Phase 3 trials ongoing — potential FDA submission in 2026–2027
- Side effects profile broadly similar to semaglutide with possibly more nausea early on
What Is CagriSema?
CagriSema is a fixed-dose combination of two molecules in a single once-weekly injection: cagrilintide (a long-acting amylin analogue) and semaglutide (the same GLP-1 active ingredient as Ozempic/Wegovy). Developed by Novo Nordisk, it targets two separate appetite-regulating pathways simultaneously — GLP-1 receptors and amylin receptors — producing additive weight loss effects.
22.7%
Average weight loss at 68 weeks (REDEFINE 1 trial)
2
Different hormonal pathways targeted simultaneously
2027
Estimated potential FDA approval date
The Amylin Pathway — Why It Matters
Amylin is a hormone co-secreted with insulin from pancreatic beta cells after meals. It acts on receptors in the brainstem (area postrema) to reduce appetite, slow gastric emptying, and improve glucose regulation — through completely different neural circuits than GLP-1. Combining both pathways produces greater appetite suppression than either drug alone.
REDEFINE 1 Trial Results
| Drug | Weight Loss at 68 weeks | ≥20% weight loss |
|---|---|---|
| CagriSema 2.4mg/2.4mg | 22.7% | 47% |
| Semaglutide alone 2.4mg | 11.8% | 20% |
| Cagrilintide alone 2.4mg | 9.6% | 13% |
| Placebo | 2.4% | 4% |
CagriSema vs Tirzepatide vs Retatrutide
| Drug | Mechanism | Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | 15–17% | Approved |
| Tirzepatide (Mounjaro) | GLP-1 + GIP | 20–22% | Approved |
| CagriSema | GLP-1 + Amylin | 22–25% | Phase 3 |
| Retatrutide | GLP-1 + GIP + Glucagon | 24% | Phase 3 |
ℹ️ When Will CagriSema Be Available?
Novo Nordisk is running multiple Phase 3 REDEFINE trials. If results confirm Phase 2/3a data, FDA/EMA submission could come in 2026 with a potential launch in 2027. Until then, tirzepatide (Mounjaro) remains the most effective approved option. Watch for REDEFINE 2–5 trial results in 2025–2026.Frequently Asked Questions
Is CagriSema better than Mounjaro?▼
Phase 3 data suggests CagriSema produces comparable or slightly more weight loss than tirzepatide. REDEFINE 1 showed 22.7% vs tirzepatide's 20–22%. However, direct head-to-head trials have not been completed. Both target different complementary pathways — future combination therapy (GLP-1 + GIP + Amylin) may be even more effective.
What are CagriSema side effects?▼
The most common side effects in REDEFINE 1 were nausea (33%), vomiting (20%), diarrhoea (17%), and constipation (26%). These are typical GLP-1 class effects amplified by the amylin component. The discontinuation rate due to side effects was higher than semaglutide alone (12% vs 3%). Dose escalation over 16 weeks reduces tolerability issues.
Is CagriSema available now?▼
No — CagriSema is not currently approved anywhere. It is in Phase 3 clinical trials (REDEFINE programme). Clinical trial participation may be available — check ClinicalTrials.gov for 'cagrilintide semaglutide'. Currently approved GLP-1 options: semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound).
Related Health Guides
Article
Retatrutide — Triple Agonist
Article
Tirzepatide vs Semaglutide
Article
Mounjaro vs Ozempic
Calculator
BMI Calculator
⚕️ Medical Disclaimer: For informational purposes only. Always consult a qualified healthcare professional before starting or changing any medication or treatment.
PS
Consultant Endocrinologist
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.